€50m · Other round · Healthtech · Lund, Sweden
Yazen, a Lund-based digital clinic for obesity care, has raised €50m in a funding round led by Verdane, with existing investor Evli Growth Partners taking a smaller participation. The company says the capital will support further European expansion of a model that combines weight-loss medication with continuous multidisciplinary care.
Retention is the product, not an add-on
Yazen treats obesity as a chronic condition rather than a short course of medication. Patients use its digital platform to work with a personal doctor and a team spanning health coaching, dietetics, psychology and physiotherapy. That service design makes ongoing clinical support part of the product: the company is selling a managed care pathway around GLP-1 treatment, not simply access to prescriptions.
The company reports more than 50,000 patients currently in treatment across eight European countries and more than 70,000 helped since launch. Its own operational data says about 70% of patients remained in treatment after 12 months. That evidence is company-reported rather than an independent trial, but it points to the commercial mechanism behind the round. In a chronic-care model, retention can improve both continuity of care and the return on the clinician, technology and acquisition costs needed to enrol each patient.
Yazen was founded by Swedish healthcare professionals in 2021. At its €19.5m Series A in 2024, it reported more than 20,000 active users and said its Swedish operation was profitable. The current patient count shows how much of the next phase has already moved beyond the home market.
Scaling care means scaling clinical operations
Yazen reported that 2025 revenue rose 87% to nearly €29.4m, while gross profit doubled to €16.5m. It also reported an EBITDA loss of €5.7m after spending more than €17.8m on marketing, showing how quickly international growth can consume capital even as the underlying service expands. The latest announcement lists 290 employees, including 210 clinical staff and 115 licensed doctors.
The €50m therefore finances more than geographic distribution. Adding countries means extending a regulated clinical operation while preserving consistent patient support, medical governance and data privacy. Verdane says those capabilities, alongside Yazen’s clinical outcomes and patient focus, shaped its investment decision. Yazen also plans to broaden treatment across cardiometabolic care. The opportunity is to spread a repeatable digital pathway across Europe; the execution test is whether clinical capacity and quality can scale as quickly as patient demand.
